Add to ORKGRituximab therapy in pulmonary alveolar proteinosis improves alveolar macrophage lipid homeostasis
Pulmonary alveolar proteinosis (PAP) is a syndrome of reduced GM-CSF-dependent, macrophage-mediated ...
Abstract: Pulmonary alveolar proteinosis is a rare condition characterized by the accumulation of li...
Pulmonary alveolar proteinosis (PAP) is a rare lung syndrome that has no cure and no FDA approved th...
RATIONALE: Pulmonary Alveolar Proteinosis (PAP) patients exhibit an acquired deficiency of biologica...
Extracted text; Rationale Pulmonary Alveolar Proteinosis (PAP) patients exhibit an acquired deficie...
Rituximab therapy in pulmonary alveolar proteinosis improves alveolar macrophage lipid homeostasi
International audienceBackground: Whole lung lavage is the current standard therapy for pulmonary al...
Pulmonary alveolar proteinosis (PAP) is a syndrome of reduced GM-CSF-dependent, macrophage-mediated ...
Abstract: Pulmonary alveolar proteinosis is a rare condition characterized by the accumulation of li...
Pulmonary alveolar proteinosis (PAP) is a rare lung syndrome that has no cure and no FDA approved th...
RATIONALE: Pulmonary Alveolar Proteinosis (PAP) patients exhibit an acquired deficiency of biologica...
Extracted text; Rationale Pulmonary Alveolar Proteinosis (PAP) patients exhibit an acquired deficie...
Rituximab therapy in pulmonary alveolar proteinosis improves alveolar macrophage lipid homeostasi
International audienceBackground: Whole lung lavage is the current standard therapy for pulmonary al...
Pulmonary alveolar proteinosis (PAP) is a syndrome of reduced GM-CSF-dependent, macrophage-mediated ...
Abstract: Pulmonary alveolar proteinosis is a rare condition characterized by the accumulation of li...
Pulmonary alveolar proteinosis (PAP) is a rare lung syndrome that has no cure and no FDA approved th...